Douglas B. Given - Sep 9, 2021 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Director
Signature
/s/Douglass Given
Stock symbol
ARWR
Transactions as of
Sep 9, 2021
Transactions value $
-$326,200
Form type
4
Date filed
9/10/2021, 04:53 PM
Previous filing
Jun 24, 2021
Next filing
Dec 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Sale -$326K -5K -4.35% $65.24 110K Sep 9, 2021 Direct F1, F2
holding ARWR Common Stock 13.9K Sep 9, 2021 By Trust F3
holding ARWR Common Stock 12.5K Sep 9, 2021 By Trust F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.20 to $65.33, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F2 Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
F3 Represents securities owned directly by Anne Given Trust ("AG Trust"). Mr. Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust.
F4 Represents securities owned directly by Katherine Given Ligtenberg Trust ("KGL Trust"). Mr. Given, as co-trustee of KGL Trust, may be deemed to beneficially own the securities owned directly by KGL Trust.